LifeSci Capital initiated coverage of Centessa (CNTA) with an Outperform rating and $37 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Centessa initiated with an Overweight at Wells Fargo
- Marvell downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls
- Centessa resumed with an Outperform at Oppenheimer
- Buy Rating on Centessa Pharmaceuticals Driven by Promising Drug Candidates and Strong Financial Position
- Centessa Pharmaceuticals: Buy Rating Driven by ORX750’s Promising Efficacy and Acquisition Potential